Please assess the completion status of the following clinical trial:

Trial Title: Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Performance status ECOG-WHO ≤ 1~* histologically proved and unresectable locally advanced or metastatic squamous cell anal carcinoma~* patient eligible to DCF regimen~* signed written informed consent~Exclusion Criteria:~* known hypersensitivity or contraindication to any of the study drugs (docetaxel, cisplatin, 5-fluorouracil).~* previous chemotherapy for metastatic disease~* previous chemotherapy by paclitaxel, docetaxel or navelbine~* previous chemotherapy by cisplatin, except of concomitant radiotherapy~* SIDA~* clinically significant cardiac disease~* other malignancy within the last 3 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer.~* simultaneous participation in another clinical study~* pregnancy, breast-feeding or absence of adequate contraception for fertile patients~* patient with any medical or psychiatric condition or disease which would make the patient inappropriate for entry into this study.~* patient under guardianship, curator or under the protection of justice.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DCF regimen (Type: EXPERIMENTAL): docetaxel 75 mg/m2 day, Cisplatin75 mg/m2 and 5Fluorouracil at 750 mg/m2/day for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).